Cellectar $CLRB posted a Q3 loss of $0.46/share, exactly in line with consensus, as the net loss widened to $8.0M on Phase 3 spending. R&D rose to $5.4M from $

Cellectar $CLRB posted a Q3 loss of $0.46/share, exactly in line with consensus, as the net loss widened to $8.0M on Phase 3 spending. R&D rose to $5.4M from $2.5M. Cash of $24.6M funds operations only into Q2 2027, so the next milestones matter: first Phase 3 dosing in Q1 2027 and a U.S. accelerat…